与虹膜松软综合征相关的药物:一项真实世界人群研究
该回顾性药物警戒队列研究基于美国食品药品监督管理局不良事件报告系统2003年10月至2024年3月的数据,分析12,345,128份不良事件报告中649例(0.0053%)虹膜松软综合征(IFIS)病例,发现丙咪嗪、坦索罗辛和氯丙嗪的报告比值比最高,三环类抗抑郁药是与IFIS关联最强的药物类别之一,且存在显著性别差异。
要点
- 丙咪嗪(ROR=251.66)、坦索罗辛(ROR=171.44)和氯丙嗪(ROR=91.30)的IFIS报告比值比最高。
- 女性中布林佐胺(ROR=409.63)和沙丁胺醇(ROR=67.12)与IFIS存在不成比例关联,男性中未观察到。
- 除α1受体阻滞剂和非典型抗精神病药外,三环类抗抑郁药也是与IFIS关联最强的药物类别之一。
核心结论
- 这些发现对于白内障手术的围手术期咨询和手术规划至关重要。
研究设计与样本
- 回顾性药物警戒临床队列研究,基于美国食品药品监督管理局不良事件报告系统2003年10月至2024年3月的数据,使用OpenVigil 2.1进行分析。
- 采用报告比值比(ROR)、比例报告比(PRR)和相对危险度减少等不成比例指标评估阳性不良反应信号(n>2,χ2>4,PRR>2),并与所有其他药物比较。
- 按性别进行亚组分析。
主要发现
- 在12,345,128份不良事件报告中,649例(0.0053%)涉及IFIS。
- 大多数病例由医疗专业人员报告(75.75%,n=203),其次为消费者(12.69%,n=34)和未知来源(11.57%,n=31)。
- IFIS不成比例最高的药物包括丙咪嗪(ROR=251.66,95%CI=157.53-402.02)、坦索罗辛(ROR=171.44,95%CI=143.12-205.36)和氯丙嗪(ROR=91.30,95%CI=49.91-167.03)(均P<.0001,IC025>0)。
- 过度报告的药物类别包括α1受体阻滞剂、三环类抗抑郁药、非典型抗精神病药、碳酸酐酶抑制剂、皮质类固醇、5α还原酶抑制剂、β受体阻滞剂、前列腺素类似物和β2受体激动剂。
- 女性中布林佐胺(ROR=409.63,95%CI=196.78-852.73)和沙丁胺醇(ROR=67.12,95%CI=28.37-158.80)与IFIS存在不成比例关联(均P<.0001,IC025>0),而男性中未观察到这些关联。
关键数值与推荐
- 阳性不良反应信号定义为n>2、χ2>4、PRR>2,并与所有其他药物比较。
- 丙咪嗪ROR=251.66(95%CI=157.53-402.02),坦索罗辛ROR=171.44(95%CI=143.12-205.36),氯丙嗪ROR=91.30(95%CI=49.91-167.03),均P<.0001且IC025>0。
- 女性中布林佐胺ROR=409.63(95%CI=196.78-852.73),沙丁胺醇ROR=67.12(95%CI=28.37-158.80),均P<.0001且IC025>0。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Intraoperative floppy iris syndrome (IFIS) is associated with an increased rate of severe intraoperative complications and greater visual morbidity during cataract surgery, particularly in females. To date, no postmarketing pharmacovigilance study has comprehensively examined all FDA-approved drugs for their association with IFIS development or explored potential sex differences. Understanding the risk factors for IFIS allows cataract surgeons to better stratify surgical risks and implement appropriate preoperative and intraoperative measures to ensure adequate management in high-risk patients. DESIGN: Retrospective pharmacovigilance clinical cohort study. METHODS: This population-based, observational study analyzed IFIS cases reported to the Food and Drug Administration Adverse Event Reporting System from October 2003 to March 2024 using OpenVigil 2.1. Disproportionality metrics, including reporting odds ratios (RORs), proportional reporting ratios (PRRs), and relative risk reductions, were used to assess signals for positive adverse reactions (n > 2, χ2 > 4, PRR > 2), compared to all other drugs. Subgroup analyses were also conducted by sex. RESULTS: Of 12,345,128 adverse event reports, 649 (0.0053%) involved IFIS. The majority of cases were reported by healthcare professionals (75.75%, n = 203), followed by consumers (12.69%, n = 34) and unknown sources (11.57%, n = 31). Drugs with the highest disproportionality for IFIS included imipramine (ROR = 251.66, 95% confidence interval [CI] = 157.53-402.02), tamsulosin (ROR = 171.44, 95% CI = 143.12-205.36), and chlorpromazine (ROR = 91.30, 95% CI = 49.91-167.03) (all P < .0001, IC025 > 0). Over-reported drug classes included α1-blockers, tricyclic antidepressants, atypical antipsychotics, carbonic anhydrase inhibitors, corticosteroids, 5α-reductase inhibitors, β-blockers, prostaglandin analogs, and β2-agonists. Among females, brinzolamide (ROR = 409.63, 95% CI = 196.78-852.73) and salbutamol (ROR = 67.12, 95% CI = 28.37-158.80) were disproportionately associated with IFIS (both P < .0001, IC025 > 0), whereas these associations were not observed in males. CONCLUSIONS: This analysis of over 20,000 drugs and 12 million reports highlights that, in addition to α1-blockers and atypical antipsychotics, tricyclic antidepressants are among the key agents most disproportionately associated with IFIS, with notable sex differences. These findings are crucial for informing perioperative counseling and surgical planning for cataract surgery.
引用
- Lakhani M, Kwan ATH, Mihalache A, et al. Drugs Associated With Floppy Iris Syndrome: A Real-World Population-Based Study. Am J Ophthalmol. 2025. PMID: 40113119. doi:10.1016/j.ajo.2025.03.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。